BioTuesdays

Category - Markets

XOMA
Markets

HCW ups XOMA PT to $56 from $30

H.C. Wainwright raised its price target for XOMA (NASDAQ:XOMA) to $56 from $30, citing the company’s growing asset base, which is linked to both increasing levels of milestone payments and future royalty potential from...

January 19, 2021
Nextgen-Logo
Markets

SVB Leerink ups NextGen Healthcare PT to $21 from $14

SVB Leerink raised its price target for NextGen Healthcare (NASDAQ:NXGN) to $21 from $14, citing unaudited preliminary fiscal third quarter results ended Dec. 31, 2020 that beat Street estimates and higher fiscal 2021...

January 13, 2021
Neoleukin-Therapeutics
Markets

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

January 6, 2021
Delcath-Systems-Inc
Markets

BTIG starts Delcath Systems at buy; PT $23

BTIG initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and price target of $23. The stock closed at $16.91 on Jan. 4. Delcath has developed HEPZATO, a percutaneous hepatic perfusion system that “we...

January 5, 2021
Kazia
Markets

HCW starts Kazia Therapeutics at buy; PT $17

H.C. Wainwright launched coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and price target of $17. The stock closed at $8.98 on Jan. 4. Kazia is developing novel therapies against brain cancer. Its lead...

January 5, 2021
Alpine Immune Sciences
Markets

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

December 21, 2020